Actively Recruiting

Phase 2
Phase 3
Age: 3Years - 17Years
All Genders
NCT06223828

Azithromycin for Critical Asthma - Pediatrics

Led by Johns Hopkins All Children's Hospital · Updated on 2025-12-17

100

Participants Needed

1

Research Sites

143 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.

CONDITIONS

Official Title

Azithromycin for Critical Asthma - Pediatrics

Who Can Participate

Age: 3Years - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 3-17 years
  • Admission to the PICU
  • Primary diagnosis of critical asthma
  • Prescription for continuous inhaled beta-agonist therapy and/or intravenous (IV) beta-agonist therapy
  • Prescription for intravenous systemic corticosteroids
Not Eligible

You will not qualify if you...

  • Critical Congenital Heart Disease Unrepaired
  • Tracheostomy Dependence at Admission
  • Ongoing Exposure to Azithromycin or Macrolide Antibiotics for any indication
  • Past Medical History of Prolonged QT Syndrome or Arrhythmias
  • Concomitant respiratory pathology including Acute Chest Syndrome, Interstitial Lung Disease, Cystic Fibrosis, and pulmonary hypertension

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Johns Hopkins All Children's Hospital

St. Petersburg, Florida, United States, 33701

Actively Recruiting

Loading map...

Research Team

A

Anthony A Sochet, MD

CONTACT

A

Alexa R Roberts, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here